Fusion protein containing membrane type RGD (arginine-glycine-aspartic acid), immune cell for expressing fusion protein and application of fusion protein
By designing membrane-type RGD fusion proteins, using RGD and integrin to recognize and inhibit tumor signals, the problem of slow progress of CAR-T cells in solid tumors was solved, significantly improving tumor infiltration and killing ability, and improving treatment effect.
Patent Information
- Application Number
- CN202411142376.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-12
AI Technical Summary
CAR-T cell therapy has progressed slowly in solid tumors, mainly due to the poor therapeutic effect caused by the high heterogeneity of solid tumors, different antigen expression on the surface of tumor cells, physical barriers to the tumor environment and immunosuppressive microenvironment.
A fusion protein containing membrane-type RGD is designed to inhibit tumor signal activation through RGD and integrin recognition, promote the tumor infiltration ability of CAR-T cells, and enhance the killing effect of CAR-T cells through membrane-type RGD structure.
It significantly improves the killing ability of CAR-T cells to solid tumors and tumor infiltration ability, improves the tumor immunosuppressive microenvironment, and enhances the therapeutic effect.
Smart Images

Figure CN118930660A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of gene engineering and tumor immunotherapy, and in particular relates to a fusion protein containing membrane-type RGD and immune cells expressing the fusion protein and applications thereof. Background Art
[0002] The treatment of malignant tumors has long faced arduous challenges. Immunotherapy has become one of the effective strategies for the treatment of malignant tumors. Its core advantage lies in stimulating the body's own immune system to fight tumors, mainly including antibody therapy, cell therapy and immunomodulator therapy. Among them, gene-modified T cell therapy has made breakthrough progress in the treatment of malignant tumors, mainly including chimeric antigen receptor gene-modified T cells (CAR-T) and T cell receptor gene-modified T cells (TCR-T). CAR-T cell therapy has made breakthrough progress in the treatment of hematological tumors, and CD19-targeted CAR-T cell products have been launched in my country. However, cell therapies such as CAR-T and TCR-T have made slow progress in solid tumors. The reasons are as follows: 1) Solid tumors are highly heterogeneous, with significant differences in the expression of tumor cell surface antigens (tumor-specific antigens and tumor-associated antigens, TSA / TAA), which in turn reduces the tumor-killing ability of immune cells such as CAR-T; 2) Tumor antigens associated with solid tumors are expressed not only in tumor tissues but may also be expressed in normal tissues, resulting in off-target effects; 3) After being delivered into the body through peripheral blood, immune cells such as CAR-T need to effectively home to the tumor site to exert their effects. However, solid tumors form solid masses, and the abundant tumor-associated fibroblasts (CAFs) and blood vessels form natural physical barriers that inhibit the homing and killing ability of cells such as CAR-T, resulting in poor treatment effects. 4) Solid tumors have an immunosuppressive microenvironment, such as regulatory T cells (Treg), myeloid-derived suppressor cells (MDSC), and M2 macrophages, which reduce the anti-tumor effect of CAR-T after reinfusion by releasing cytokines such as transforming growth factor β (TGFβ) and interleukin-10 (IL-10).
[0003] The integrin family is a family of membrane receptors composed of multiple proteins with similar structures and functions. In mammals, 24 transmembrane heterodimeric glycoproteins with different functions formed by 18 α subunits and 8 β subunits have been found. The α and β subunits jointly determine the receptor properties of integrins. Integrins are the main cell adhesion transmembrane receptors. They act as biochemical and mechanical signal transducers between extracellular matrix (ECM) and skeleton connectors, cells and their environment, and are important mediators of the density of malignant tumors. Studies have shown that integrins are significantly highly expressed in a variety of malignant tumors such as osteosarcoma, lung cancer, prostate cancer, breast cancer, and bladder cancer, and they promote malignant phenotypes such as tumor cell proliferation, migration and invasion after connecting with ECM. In 1970, it was found that (Arg-Gly-Asp) RGD tripeptide is the binding group of integrin and can be used as a cell adhesion ligand. RGD has a high affinity with integrins overexpressed on cancer cells, which can achieve targeted diagnosis and treatment of tumors.
[0004] Based on the current state of the prior art, the inventors of the present application intend to provide a method for preparing and applying an immune cell carrying a membrane-type RGD fusion protein and expressing the fusion protein. Summary of the invention
[0005] The purpose of the present invention is to provide a fusion protein containing membrane-type RGD and immune cells expressing the fusion protein and applications thereof.
[0006] In order to achieve the purpose of the present invention, in a first aspect, the present invention provides a fusion protein containing membrane-type RGD, wherein the fusion protein comprises a membrane-type RGD fusion protein or a membrane-type tandem RGD fusion protein and a CAR structure (chimeric antigen receptor), and the CAR structure is located at the C-terminus of the fusion protein.
[0007] The present invention adopts RGD membrane-anchored expression design, 1) through the tumor targeting of RGD, the tumor infiltration ability of CAR-T cells is promoted; 2) RGD and integrin recognition inhibit integrin activation signals, thereby inhibiting the malignant phenotype of the tumor and relieving the tumor immunosuppressive microenvironment; 3) The membrane-type RGD has a small molecular weight of only about 300bp and has no effect on the expression of the CAR structure; multiple RGD molecules can be connected in series to further enhance the tumor infiltration ability of CAR-T cells.
[0008] Furthermore, the structure of the membrane-type RGD peptide is: RGD peptide-CD8a hinge region-CD8a transmembrane region.
[0009] Furthermore, the structure of the membrane-type tandem RGD peptide is: RGD peptide-Linker-Flag tag-Linker-RGD peptide-CD8a hinge region-CD8a transmembrane region.
[0010] In the present invention, the RGD peptide is a small peptide comprising an arginyl-glycyl-aspartic acid structure, and the preferred amino acid sequence is: ACDCRGDCFCG.
[0011] Furthermore, the CAR structure includes an antigen binding domain, a hinge region, a transmembrane region and an intracellular signaling domain (including a co-stimulatory domain and a signal transduction domain).
[0012] Furthermore, in the tandem RGD peptide, the Flag tag is DYKDDDDK, and the Linker is (GGGGS) n , n is an integer from 1 to 100, preferably n is 1.
[0013] Furthermore, the CAR structure is: anti-PMSA scFv (single-chain variable fragment)-CD28 hinge region-CD28 transmembrane region-41BB-CD3ζ.
[0014] Furthermore, the membrane-type RGD peptide or the membrane-type tandem RGD peptide and the CAR structure are self-cleaving peptides.
[0015] Furthermore, the self-cleaving peptide is a 2A peptide, such as T2A, P2A, E2A or F2A.
[0016] In a second aspect, the present invention provides a nucleic acid molecule encoding the fusion protein.
[0017] In a third aspect, the present invention provides biological materials containing the nucleic acid molecules.
[0018] The biological material includes, but is not limited to, recombinant DNA, expression cassette, transposon, plasmid vector, viral vector, engineered bacteria or transgenic cell line.
[0019] In a fourth aspect, the present invention provides an immune cell expressing the fusion protein, which is constructed by introducing a gene encoding the fusion protein into the immune cell via a vector (such as a lentiviral vector).
[0020] Furthermore, the immune cells are immune cells derived from mammals, such as T lymphocytes (T cells), natural killer cells (NK cells), monocytes, neutrophils, macrophages or dendritic cells (DC cells) and the like.
[0021] Preferably, the immune cells are T cells.
[0022] The T cells further express a T cell receptor (TCR) that binds to the tumor antigen.
[0023] The schematic diagram of the structure of the membrane-type RGD CAR-T cell provided by the present invention is shown in Figure 1 .
[0024] In a fifth aspect, the present invention provides the use of the immune cells in the preparation of anti-tumor drugs or compositions.
[0025] In a sixth aspect, the present invention provides the use of the immune cells in tumor treatment.
[0026] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects: (I) The present invention uses RGD as an integrin-specific recognition peptide, which has been used in imaging diagnosis and disease treatment, and its effectiveness and safety have been fully verified. RGD, as an integrin-specific ligand, has good tumor targeting.
[0027] (II) The present invention constructs membrane-type RGD CAR-T cells. On the one hand, it targets integrins to fully inhibit the interstitial protection and malignant phenotype of tumors; on the other hand, it can effectively improve the tumor immunosuppressive microenvironment and promote the infiltration and killing ability of CAR-T cells on solid tumors.
[0028] (III) Experimental results indicate that the new cell therapy product (RGD CAR-T cells) expressing membrane-type RGD provided by the present invention has no significant difference in infection efficiency compared with ordinary CAR-T cells, and functional experimental results indicate that the membrane-type RGD structure significantly increases the killing effect of CAR-T cells on solid tumors in vitro and in vivo, as well as the tumor infiltration ability. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 Schematic diagram of the structure of membrane-type RGD CAR-T cells in a preferred embodiment of the present invention.
[0030] Figure 2 It is a schematic diagram of the structure of the nucleic acid construct in a preferred embodiment of the present invention.
[0031] Figure 3 In the preferred embodiment of the present invention, the expression of CAR is detected by PSMA fluorescent protein (A), and the expression of RGD is detected by Flag antibody (B).
[0032] Figure 4 In the preferred embodiment of the present invention, the expression levels of PSMA and αv integrin (ITGAV) in 3 prostate cancer organoids were detected by fluorescent quantitative PCR.
[0033] Figure 5 The detection of cytokine secretion and killing ability of CAR-T cells co-incubated with prostate cancer organoid tumor cells in the preferred embodiment of the present invention. Among them, A: ELISA kit (R&D) detects the secretion level of cytokines in the supernatant of CAR-T cells co-incubated with organoids. B: Flow cytometry detects the killing effect of CAR-T cells on organoids.
[0034] Figure 6 In vivo detection of the killing ability of CAR-T cells on tumor cells in a preferred embodiment of the present invention. A: Comparison results of tumor volume. B: Immunofluorescence detection of CD3 positive T cell infiltration in tumors. DETAILED DESCRIPTION
[0035] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.
[0037] In the following examples, membrane-type RGD and PSMA CAR are connected through T2A so that T cells express membrane-type RGD and PSMA CAR at the same time. The use of T2A can ensure that the expression efficiency of membrane-type RGD and PSMA CAR in T cells is relatively consistent. On the one hand, it is convenient to indirectly evaluate the membrane anchoring of membrane-type RGD, and on the other hand, it can evaluate the effect of membrane-type RGD on the function of PSMA CAR-T cells.
[0038] Example 1 Method for constructing T cells that simultaneously express membrane-type RGD fusion protein and CAR
[0039] This example takes the membrane-type RGD CAR-T cells targeting prostate-specific membrane antigen (PMSA) as an example, and constructs a lentiviral vector that simultaneously expresses PSMA CAR and membrane-type RGD fusion protein. The specific construction method is as follows: After extensive screening, two RGD membrane-type fusion proteins (RGD monomer and tandem RGD) were obtained. The amino acid sequences of the hinge region and transmembrane region of CD8a are shown in SEQ ID NOs: 5 and 6. Then, the above sequences were added after RGD and Tandem RGD to form membrane-type mRGD-CD8a and Tandem mRGD-CD8a, respectively. In order to facilitate the expression detection of the above fusion proteins, flag tags (amino acid sequence: DYKDDDDK, nucleotide sequence: GACTACAAGGACGACGACGACAAG) were added to form flag-mRGD-CD8a (SEQ ID NO: 7) and mRGD-linker-flag-linker-mRGD-CD8a (SEQ ID NO: 8), respectively. The above sequences were connected to PSMA CAR (SEQ ID NO: 9) through T2A (amino acid sequence: EGRGSLLTCGDVEENPGP, nucleotide sequence: GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCT), respectively, to form mRGD-PSMA BBz (SEQ ID NO: 1) and Tandem-mRGD -PSMA BBz (SEQ ID NO: 3), respectively. Their nucleotide sequences are shown in SEQ ID NO: 4. NO:2 and SEQ ID NO:4, respectively, and the whole gene synthesis was performed. The structural schematic diagram is shown in Figure 2 , and cloned into the lentiviral vector pLVx-EF1a-IRES-puro (purchased from Yunzhou Biotechnology (Guangzhou) Co., Ltd.) through double digestion with EcoR I and BamH I, and named pLVx-EF1a-PSMA BBz, pLVx-EF1a-mRGD-PSMA BBz, and pLVx-EF1a-Tandem-mRGD-PSMA BBz, respectively.
[0040] The construction method of the pLVx-EF1a-PSMA BBz recombinant lentiviral vector includes: (1) Synthesize the nucleotide sequence of PSMA BBz (SEQ ID NO: 10), add EcoR I and BamH I restriction sites at both ends of the nucleotide sequence, and clone it into the pUC57 vector; (2) Double digest the pUC57 vector containing the target gene with EcoR I and BamH I, and then cut the gel to recover the target gene fragment; (3) The original vector pLVx-EF1a-IRES-puro was double-digested with EcoR I and BamH I, and the vector fragment of about 9 Kb was recovered by gel excision; (4) Use DNA ligase to connect and recover the target fragment and the vector fragment to obtain the recombinant lentiviral vector carrying pLVx-EF1a-PSMA BBz.
[0041] The construction method of the pLVx-EF1a-mRGD-PSMA BBz recombinant lentiviral vector includes: (1) Synthesize the nucleotide sequence of mRGD-PSMA BBz (SEQ ID NO: 2), add EcoR I and BamH I restriction sites at both ends of the nucleotide sequence, and clone it into the pUC57 vector; (2) Double digest the pUC57 vector containing the target gene with EcoR I and BamH I, and then cut the gel to recover the target gene fragment; (3) The original vector pLVx-EF1a-IRES-puro was double-digested with EcoR I and BamH I, and the vector fragment of about 9 Kb was recovered by gel excision; (4) Use DNA ligase to connect and recover the target fragment and the vector fragment to obtain the recombinant lentiviral vector carrying pLVx-EF1a-mRGD-PSMABBz.
[0042] The construction method of the pLVx-EF1a-Tandem-mRGD-PSMA BBz recombinant lentiviral vector includes: (1) Synthesize the nucleotide sequence of Tandem-mRGD-PSMA BBz (SEQ ID NO: 4), add EcoR I and BamH I restriction sites at both ends of the nucleotide sequence, and clone it into the pUC57 vector; (2) Double digest the pUC57 vector containing the target gene with EcoR I and BamH I, and then cut the gel to recover the target gene fragment; (3) The original vector pLVx-EF1a-IRES-puro was double-digested with EcoR I and BamH I, and the vector fragment of about 9 Kb was recovered by gel excision; (4) Use DNA ligase to connect and recover the target fragment and the vector fragment to obtain the recombinant lentiviral vector carrying pLVx-EF1a-Tandem-mRGD-PSMA BBz.
[0043] Example 2 Preparation of Lentivirus
[0044] The recombinant lentiviral vector prepared in Example 1 was transfected into 293FT cells using a transfection reagent (PEI) to produce lentivirus. The specific method includes: The packaging plasmid mixture (psPAX2: pMD2G = 1:1, mass ratio) and each lentiviral vector were added to 500 μL of serum-free medium opti-MEM at a mass ratio of 2:1 and vortexed to mix thoroughly. 42 μg of PEI was added to 500 μL of serum-free medium opti-MEM and vortexed to mix thoroughly. Then the plasmid and PEI mixture was thoroughly mixed and added to 293FT cells with a confluence of 90%. The virus supernatants were collected at 48 hours and 72 hours, respectively, and the viruses were concentrated 100 times by ultracentrifugation to obtain concentrated lentivirus.
[0045] Example 3 Preparation of CAR-T cells
[0046] Peripheral blood T cells from healthy volunteers were infected with the above-mentioned lentivirus, and T cell culture medium (formula: X-VIVO15 culture medium + 100 U / mL IL-2 + 50 ng / mL OKT3 + 1 μg / mL CD28 antibody), PE-labeled PSMA fluorescent protein and flag antibody were used for flow cytometry detection of the infection efficiency of PSMA CAR and membrane-type RGD, respectively.
[0047] The results showed that the expression efficiency of PSMA CAR without T2A connection was slightly higher, and the expression of mRGD-PSMA CAR and Tandem-mRGD-PSMA CAR was slightly lower, with no statistical difference ( Figure 3 ).
[0048] Example 4 Identification of CAR-T cell functions in vivo and in vitro
[0049] Three prostate cancer organoids (PCa-organoid-1, PCa-organoid-2, and PCa-organoid-3) were resuscitated and 2 × 10 organoid cells were collected from each organoid. 6, add 1 mL Trizol and mix well, let stand at room temperature for 5 minutes, add 0.2 mL chloroform, shake vigorously for 15 seconds, let stand at room temperature for 5 minutes, centrifuge at 12000 g for 15 minutes, take the upper aqueous phase, add 0.5 mL isopropanol, mix gently, let stand at room temperature for 10 minutes, centrifuge at 12000 g for 15 minutes, discard the supernatant, add 1 mL 75% ethanol and mix gently, centrifuge at 12000 g for 15 minutes, discard the supernatant, dissolve the precipitate in pure water, and obtain the total RNA of the organoid. Prepare the reverse transcription system according to the following ratio: RTMaster Mix 2 μL, RNA 500 ng, make up the volume to 10 μL with pure water, mix and centrifuge. Perform reverse transcription PCR according to the following system: 37℃ 15 minutes, 85℃ 5 seconds, 4℃, 10 minutes; obtain organoid cDNA. The reaction system was prepared according to the following ratio: SYBR Premix Ex Taq 10 μL, forward primer 0.4 μM, reverse primer 0.4 μM, ROX Dye 0.4 μL, cDNA 1 μL, and pure water was added to 20 μL. Fluorescence quantitative PCR was performed according to the following system: the first step was pre-denaturation at 95°C for 30 seconds, the second step was PCR reaction at 95°C for 5 seconds, and 65°C for 30 seconds (cycle number 40), GAPDH was used as an internal reference, and the expression of PSMA and αv integrin (ITGAV) in organoids was detected ( Figure 4 ). This indicates that both PCa-organoid-2 and PCa-organoid-3 highly express PSMA, while PCa-organoid-1 does not express PSMA. All three organoids express ITGAV, with PCa-organoid-2 expressing the highest level.
[0050] The PCR primer sequences are as follows (5′-3′): PSMA: Forward primer: TCAGTGAGAGACTCCAGGACTT
[0051] Reverse primer: AAAGGCCTGTCTGGTAACCC
[0052] ITGAV: Forward primer: TCACTAAGCGGGATCTTGCC
[0053] Reverse primer: AGATTGCACTCTTTCCTCTGTCT
[0054] GAPDH: Forward primer: GCTGAGTACGTCGTGGAGTC
[0055] Reverse primer: ATGACGAACATGGGGGCATC
[0056] mRGD-PSMA BBz, Tandem-mRGD -PSMA BBz and PSMA BBz CAR-T cells were incubated with 5×10 4 After 24 hours of co-incubation of organoid tumor cells at an effector-target ratio of 2:1, the concentrations of IL2, TNFα and IFN-γ in the supernatant were detected. The results showed that the cytokine secretion levels of the mRGD-PSMA BBz and Tandem-mRGD -PSMA BBz groups were significantly higher than those of the PSMACAR-T group, and the Tandem-mRGD PSMA BBz group was significantly higher than that of the mRGD-PSMA BBz.
[0057] mRGD-PSMA BBz, Tandem-mRGD -PSMA BBz and PSMA BBz CAR-T cells were co-incubated with CFSE pre-labeled organoid cells at effector-target ratios of 20:1, 10:1, 5:1, and 1:1, respectively, and the cell death ratio (PI-positive target cell percentage) in CFSE-labeled target cells was identified by flow cytometry. The results showed that the killing effects of mRGD-PSMA BBz and Tandem-mRGD -PSMABBz were significantly better than those of the PSMA BBz group, and the Tandem-mRGD BBz group was significantly higher than that of the mRGD-PSMA BBz group ( Figure 5 ).
[0058] mRGD-PSMA BBz, Tandem-mRGD -PSMA BBz and PSMA BBz CAR-T cells (1×10 7 The results showed that the CAR-T cells of mRGD-PSMA BBz and Tandem-mRGD -PSMA BBz had significantly stronger tumor cell killing ability in vivo than PSMA BBz CAR-T cells ( Figure 6 A). The infiltration level of human CD3-positive T cells in tumor tissue was detected by immunofluorescence (green: CD3, blue: cell nucleus). The results showed that membrane-type RGD significantly promoted the infiltration level of CAR-T cells in tumors ( Figure 6 B).
[0059] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A fusion protein containing membrane-type RGD, characterized in that: The fusion protein comprises a membrane-type RGD peptide or a membrane-type tandem RGD peptide and a CAR structure, and the CAR structure is located at the C-terminus of the fusion protein; The CAR structure includes an antigen binding domain, a hinge region, a transmembrane region and an intracellular signaling domain; The structure of the membrane-type RGD peptide is: RGD peptide-CD8a hinge region-CD8a transmembrane region; The structure of the membrane-type tandem RGD peptide is: RGD peptide-Linker-Flag tag-Linker-RGD peptide-CD8a hinge region-CD8a transmembrane region; The RGD peptide is a small peptide containing an arginyl-glycyl-aspartic acid structure, and the preferred amino acid sequence is: ACDCRGDCFCG.
2. The fusion protein according to claim 1, characterized in that In the tandem RGD peptide, the Flag tag is DYKDDDDK, and the Linker is (GGGGS) n , n is an integer from 1 to 100.
3. The fusion protein according to claim 1, characterized in that The CAR structure is: anti-PMSA scFv-CD28 hinge region-CD28 transmembrane region-41BB-CD3ζ.
4. The fusion protein according to any one of claims 1 to 3, characterized in that The membrane-type RGD peptide or the membrane-type tandem RGD peptide and the CAR structure are separated by a self-cleaving peptide; The self-cleaving peptide is a 2A peptide, and the 2A peptide is T2A, P2A, E2A or F2A.
5. A nucleic acid molecule encoding the fusion protein according to any one of claims 1 to 4 and a biological material containing the nucleic acid molecule; The biological material is recombinant DNA, expression cassette, transposon, plasmid vector, virus vector, engineering bacteria or transgenic cell line.
6. An immune cell expressing the fusion protein according to any one of claims 1 to 4, characterized in that: It is constructed by introducing the gene encoding the fusion protein into immune cells via a vector; The immune cells are immune cells derived from mammals.
7. The immune cell according to claim 6, characterized in that The immune cells include T lymphocytes, natural killer cells, monocytes, neutrophils, macrophages or dendritic cells.
8. The immune cell according to claim 6, characterized in that The immune cells are T cells.
9. The immune cell according to claim 8, characterized in that The T cells further express a T cell receptor that binds to the tumor antigen.
10. Use of the immune cell according to any one of claims 6 to 9 in the preparation of an anti-tumor drug or composition.
